Work

Abstract PS2-10-19: Circulating tumor DNA (ctDNA) as a strong prognostic biomarker of minimal residual disease (MRD) using a tissue-free, epigenomic assay in early-stage breast cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-10-19

Authors: W. Janni, B. Rack, P. A. Fasching, A. Hartkopf, H. Tesch, R. Lorenz, G. Heinrich, J. Blohmer, T. Fehm, V. Müller, A. Schneeweiss, M. W. Beckmann, M. Rübner, N. Harbeck, K. Pantel, D. Dustin, M. Cai, T. W. Friedl

Institutions: University Hospital Ulm, Universitätsklinikum Erlangen, Universitätsklinikum Tübingen, Charité - Universitätsmedizin Berlin, Düsseldorf University Hospital, University Medical Center Hamburg-Eppendorf, German Cancer Research Center, LMU Klinikum, Ludwig-Maximilians-Universität München, Guardant (United States)

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7130700246

Cites:

Cited by:

Related to: